Clinical, in vivo, and in vitro studies have demonstrated that age, race, immune responses, hormones, hormone receptor expression, the epigenetic and genetic alterations all can vary between tumors from male and female bladder cancer patients (summarized in Table 1). The gene discussed is NR4A1; the disease is urinary bladder cancer.